Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New palliative care program aims to ease suffering for dementia patients and families

NCT ID NCT04948866

Symptom relief Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a special palliative care program for people with late-stage Alzheimer's or related dementias and their family caregivers. The program started during a hospital stay and included caregiver education and support to reduce hospital transfers and improve symptom control. Researchers enrolled 884 participants to see if this approach could lessen burdens on both patients and caregivers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Palliative care program including caregiver education and transitional care
What this could lead to
If successful, this program could improve quality of life for patients and reduce stress for caregivers by better managing symptoms and avoiding unnecessary hospital stays.
What could go wrong
This is a completed study, so results are available but may not apply to all settings. The program requires hospital-based triggers, which may limit its use in other care environments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

884 people

The number who actually took part.

Started

Jul 2021

Finished

Feb 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: People with ADRD Inclusion Criteria: * aged 55 or older * hospitalized * have a physician-confirmed diagnosis of ADRD * staged GDS 6 or 7; or GDS 5 with additional co-morbidity defined by Charlson Comorbidity Index scored 5 or higher Caregiver Inclusion Criteria: * the adult (aged 18 or older) legally authorized representative (LAR) for healthcare and have capacity to serve in this role * support the person with ADRD * can complete interviews in English or Spanish. Exclusion Criteria: Dyads will be excluded if * the LAR is not a family caregiver * the patient currently receives palliative care or hospice * patient or caregiver would be unduly stressed * dyad is not successfully randomized.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease dementia frontotemporal dementia Lewy body dementia Lewy Body Disease Mixed Dementias vascular dementia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer disease Dementia Dementia alzheimers Dementia frontal Dementia severe Dementia with lewy bodies Dementia, mixed Dementia, vascular

Contacts and locations

Locations

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02215, United States

  • University of Colorado Denver

    Denver, Colorado, 80045, United States

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.